A New Topical Eye Drop Containing LyeTxI-b, A Synthetic Peptide Designed from A Lycosa erithrognata Venom Toxin, Was Effective to Treat Resistant Bacterial Keratitis

Autor(es):Mostrar menos -

da Silva, Carolina Nunes ^[1] ; da Silva, Flavia Rodrigues ^[2] ; Nunes Dourado, Lays Fernanda ^[1] ; Mendes dos Reis, Pablo Victor ^[3] ; Silva, Rummenigge Oliveira ^[1] ; da Costa, Bruna Lopes ^[1] ; Nunes, Paula Santos ^[2] ; Amaral, Flavio Almeida ^[3] ; dos Santos, Vera Lucia ^[4] ; de Lima, Maria Elena ^[5] ; Cunha Junior, Armando da Silva ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Minas Gerais, Fac Farm, BR-31270901 Belo Horizonte, MG - Brazil

^[2] Univ Fed Sergipe, PPGCAS, BR-49400000 Lagarto, SE - Brazil

^[3] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG - Brazil

^[4] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG - Brazil

^[5] Grp Santa Casa Belo Horizonte, Programa Posgrad Ciencias Saude Biomed & Med, Ensino & Pesquisa Santa Casa Belo Horizonte, BR-30150250 Belo Horizonte, MG - Brazil

• Tipo de documento: Artigo Científico
• Fonte: TOXINS; v. 11, n. 4 APR 2019.
• Citações Web of Science: 0

Resumo

Bacterial keratitis is an ocular infection that can lead to severe visual disability. Staphylococcus aureus is a major pathogen of the eye. We recently demonstrated the strong antimicrobial activity of LyeTxI-b, a synthetic peptide derived from a Lycosa erithrognatha toxin. Herein, we evaluated a topical formulation (eye drops) containing LyeTxI-b to treat resistant bacterial keratitis. Keratitis was induced with intrastromal injection of 4 x 10(5) cells (4 mu L) in New Zealand female white rabbits. Minimum inhibitory concentration (MIC) and biofilm viability were determined. LyeTxI-b ocular toxicity was evaluated through chorioallantoic membrane and Draize tests. One drop of the formulation (LyeTxI-b 28.9 mu mol/L +0.5% CMC in 0.9% NaCl) was instilled into each eye four times a day, for a week. Slit-lamp biomicroscopy analysis, corneal histopathological studies and cellular infiltrate quantification through myeloperoxidase (MPO) and N-acetylglucosaminidase (NAG) detection were performed. LyeTxI-b was very effective in the treatment of keratitis, with no signs of ocular toxicity. Planktonic bacteria MIC was 3.6 mu mol/L and LyeTxI-b treatment reduced biofilm viability in 90%. LyeTxI-b eliminated bacteria and reduced inflammatory cellular activity in the eyes. Healthy and treated animals showed similar NAG and MPO levels. LyeTxI-b is a potent new drug to treat resistant bacterial keratitis, showing effective antimicrobial and anti-inflammatory activity. (AU)

• Processo FAPESP: 14/50928-2 - INCT 2014: Nanotecnologia Farmacêutica: uma abordagem transdisciplinar
• Beneficiário: Maria Vitória Lopes Badra Bentley
• Modalidade de apoio: Auxílio à Pesquisa - Temático